Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Travoprost: a potent ocular hypotensive agent.

Adel M Al-Jazzaf1, Louis DeSantis, Peter A Netland

  • 1Department of Ophthalmology, University of Tennessee Health Science Center, 956 Court Avenue, Suite D228, Memphis, TN 38163, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 2, 2003
PubMed
Summary

Travoprost, a prostaglandin analogue, effectively treats glaucoma and ocular hypertension by reducing intraocular pressure. This topical medication is safe and convenient for daily use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyphema Associated with Water Bead Projectile Toys: A Retrospective Comparative Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Ahmed Glaucoma Valve in Aniridia.

Clinical ophthalmology (Auckland, N.Z.)·2025
Same author

Hyperreflective Dots in Central Fovea Visualized by a Novel Application of Visible-Light Optical Coherence Tomography.

Case reports in ophthalmological medicine·2024
Same author

Comparative In Vivo Imaging of Retinal Structures in Tree Shrews, Humans, and Mice.

eNeuro·2024
Same author

Visible-Light Optical Coherence Tomography Fibergraphy of the Tree Shrew Retinal Ganglion Cell Axon Bundles.

IEEE transactions on medical imaging·2024
Same author

Neural damage and neuroprotection with glaucoma development in aniridia.

Current neurobiology·2023

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma and ocular hypertension are conditions characterized by elevated intraocular pressure.
  • Current treatments aim to reduce intraocular pressure to prevent optic nerve damage.

Purpose of the Study:

  • To evaluate the efficacy and safety of travoprost as a topical treatment for elevated intraocular pressure.
  • To assess travoprost's mechanism of action in reducing intraocular pressure.

Main Methods:

  • Phase II and III clinical studies were conducted for FDA approval.
  • Travoprost's affinity and activity at prostaglandin receptors were assessed.
  • The effect of travoprost on uveoscleral outflow was investigated.

Main Results:

  • Travoprost demonstrated high affinity and full agonist activity for the FP prostaglandin receptor.

Related Experiment Videos

  • Topical travoprost effectively reduced elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
  • Common side effects included hyperemia, eyelash growth, and iris color change.

    • Conclusions:

    • Travoprost is an effective and safe topical agent for managing elevated intraocular pressure.
    • The drug's mechanism involves increased uveoscleral outflow.
    • Travoprost offers a convenient once-daily dosing regimen without requiring refrigeration.